Zymeworks Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
/ 
Frequently asked questions
To buy Zymeworks Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Zymeworks Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Zymeworks Inc. is ZYME:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Zymeworks Inc. has its primary listing on NASDAQ. You can trade Zymeworks Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Zymeworks Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Zymeworks Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Zymeworks Inc..